source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech→ AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…Endpoints · 1h ago↗ source